financetom
Business
financetom
/
Business
/
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $437,325, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $437,325, According to a Recent SEC Filing
Sep 25, 2024 2:19 PM

04:42 PM EDT, 09/25/2024 (MT Newswires) -- Eben Tessari, COO, on September 23, 2024, sold 17,500 shares in Kiniksa Pharmaceuticals International (KNSA) for $437,325. Following the Form 4 filing with the SEC, Tessari has control over a total of 116,975 shares of the company, with 116,975 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1730430/000141588924023954/xslF345X05/form4-09252024_080916.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Textron Weighs Alternatives for Powersports Product Line
Textron Weighs Alternatives for Powersports Product Line
Dec 18, 2024
11:04 AM EST, 12/18/2024 (MT Newswires) -- Textron ( TXT ) is looking into strategic alternatives for its powersports product line, according to a regulatory filing Wednesday. The company said its specialized vehicles business has started to pause production of its powersports products as management weighs options. Powersports products will be paused indefinitely in the first half of 2025 after...
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
Dec 18, 2024
Cognition Therapeutics, Inc. ( CGTX ) revealed positive results from the exploratory Phase 2 SHIMMER study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with dementia with Lewy bodies (DLB). The SHIMMER Phase 2 study enrolled 130 patients with mild-to-moderate DLB who were randomized to receive one of two oral doses of CT1812 or placebo...
--Brooge Energy Shareholders File Fraud Complaint Against Ernst & Young, Reuters Reports
--Brooge Energy Shareholders File Fraud Complaint Against Ernst & Young, Reuters Reports
Dec 18, 2024
11:02 AM EST, 12/18/2024 (MT Newswires) -- Price: 1.47, Change: -0.12, Percent Change: -7.26 ...
Weight loss drugs could help end obesity - but risks remain, WHO says
Weight loss drugs could help end obesity - but risks remain, WHO says
Dec 18, 2024
LONDON, Dec 18 (Reuters) - A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly ( LLY ) opens the possibility of an end to the obesity pandemic alongside other interventions, the World Health Organization (WHO) said this week. But the global health agency said it has concerns that unless health systems prepare properly, the drugs...
Copyright 2023-2026 - www.financetom.com All Rights Reserved